Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics Inc (NQ: DYN )

25.83 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 25.83
Bid (Size) 25.83 (6)
Ask (Size) 27.60 (15)
Prev. Close 25.83
Today's Range 25.83 - 25.83
52wk Range 6.400 - 30.27
Shares Outstanding 58,310,703
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
From Dyne Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+97.78%
+97.78%
1 Month
-7.75%
-7.75%
3 Month
+20.70%
+20.70%
6 Month
+253.84%
+253.84%
1 Year
+123.44%
+123.44%

More News

Read More
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Recap: Dyne Therapeutics Q4 Earnings
Via Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Dyne Therapeutics Announces CEO Transition
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
Via Benzinga
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Chardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Know
Via Benzinga
Piper Sandler Maintains Overweight Rating for Dyne Therapeutics: Here's What You Need To Know
Via Benzinga
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Top 4 Health Care Stocks You May Want To Dump In February
Via Benzinga
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present at February Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
7 Speculative Stocks to Double Your Money THIS Year
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
$30M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Crude Oil Moves Lower; Walgreens Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.